The company develops prescription drugs, over-the-counter drugs, and diagnostic products for therapeutic areas including metabolic disorders, pain/CNS, infectious diseases and cancer, and offers contract development and manufacturing facilities. Shionogi provides products and services in Japan, Europe, North America, and other regions, positioning itself as a diversified specialty and generic pharmaceutical manufacturer with global reach.
Cyborg Score Rationale
With 2025 revenue of $3.0B and market cap of $19.4B, Shionogi demonstrates stable financial performance. The company's portfolio of established brands (Crestor, Ilbetan, Sinbalta) provides revenue stability, though the company faces competitive pressures from larger pharma players and antibiotic market headwinds.
Top Insights
Shionogi is a partial owner of ViiV Healthcare, a pharmaceutical company specializing in HIV therapies
The company operates a network of subsidiaries across Japan, China, Taiwan, North America, and Europe, headquartered in Osaka
Recent M&A activity includes a corporate deal with Salubritas Therapeutics (December 2025)
Shionogi has business roots dating back to 1878 and was incorporated in 1919
Named Competitors
Takeda Pharmaceutical — Diversified Japanese pharma with global reach
Astellas Pharma — Japanese specialty pharmaceutical company
Chugai Pharmaceutical — Japanese pharma focusing on oncology and diagnostics
Novartis — Global innovative pharmaceutical company
Recent Developments
(December 2025) Shionogi completed corporate deal with Salubritas Therapeutics
(September 2025) Highlighted Japan's role in global health in discussion with Bill Gates on infectious diseases
(August 2025) Selected for METI's FY2024 Supplementary Grant Program for co-creation initiatives with Global South
Open the full interactive Shionogi & Co., Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.